Carboplatin

Suppliers

Names

[ Name ]:
Carboplatin

[Synonym ]:
Diammine[1,1-cyclobutanedicarboxylato(2-)-κO,O]platinum
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
Platinum(2+) 1,1-cyclobutanedicarboxylate diammoniate
cbdca
MFCD00070464
(SP-4-2)-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
[Cyclobutane-1,1-dicarboxylato(2-)-κO,O]platinum diammoniate
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
[1,1-Cyclobutanedicarboxylato(2-)-κO,O]platinum diammoniate
Platinum, [1,1-cyclobutanedicarboxylato(2-)-κO,κO]-, ammoniate (1:2)
JM-8
PARAPLATIN
cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II)
PARAPLATIN(R)
CARBONPLATIN
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
CARBOPLATINUM
diammine[cyclobutane-1,1-dicarboxylato(2-)-κ2O1,O1]platinum
cis-diammmine(1,1-cyclobutanedicarboxylato)platinum(II)
Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-κO,κO]-
EINECS 255-446-0
Carboplatin
diammine(cyclobutane-1,1-dicarboxylato)platinum(II)
platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-κO1,κO1]-

Chemical & Physical Properties

[ Boiling Point ]:
366.4ºCat 760 mmHg

[ Melting Point ]:
228-230ºC

[ Molecular Formula ]:
C₆H₁₂N₂O₄Pt

[ Molecular Weight ]:
371.254

[ Flash Point ]:
189.6ºC

[ Exact Mass ]:
371.044495

[ PSA ]:
59.08000

[ LogP ]:
0.81700

[ Storage condition ]:
Store at RT

[ Stability ]:
Stable. Incompatible with strong oxidizing agents.

[ Water Solubility ]:
Sparingly soluble in water, very slightly soluble in acetone and in ethanol (96 per cent). | Soluble in water.

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TP2300000

CHEMICAL NAME :: Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-

CAS REGISTRY NUMBER :: 41575-94-4

LAST UPDATED :: 199803

DATA ITEMS CITED :: 33

MOLECULAR FORMULA :: C6-H12-N2-O4-Pt

MOLECULAR WEIGHT :: 371.29

WISWESSER LINE NOTATION :: L4TJ AVQ AVQ &Z-PT-Z

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 343 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 72 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 60900 ug/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - effect, not otherwise specified Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 118 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 89360 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 180 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >31200 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Mammal - species unspecified

DOSE/DURATION :: 158 mg/kg

TOXIC EFFECTS :: Tumorigenic - active as anti-cancer agent

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 70 mg/kg/2W-I

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - changes in lung weight Endocrine - changes in spleen weight Blood - changes in platelet count

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 140 mg/kg/26W-I

TOXIC EFFECTS :: Blood - normocytic anemia Blood - changes in bone marrow (not otherwise specified) Blood - changes in leukocyte (WBC) count

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 60 mg/kg/5D-I

TOXIC EFFECTS :: Gastrointestinal - alteration in gastric secretion Gastrointestinal - other changes Blood - hemorrhage

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 24 mg/kg

SEX/DURATION :: female 6-9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 24 mg/kg

SEX/DURATION :: female 6-9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: Micronucleus test

TYPE OF TEST :: DNA damage

TYPE OF TEST :: DNA inhibition

TYPE OF TEST :: Mutation test systems - not otherwise specified

TYPE OF TEST :: Cytogenetic analysis

MUTATION DATA

TYPE OF TEST :: Morphological transformation

TEST SYSTEM :: Rodent - hamster Kidney

DOSE/DURATION :: 25 umol/L

REFERENCE :: EJCODS European Journal of Cancer and Clinical Oncology. (Pergamon Press, c/o Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.17(7)- 25, 1981-89. For publisher information, see EJCAEL Volume(issue)/page/year: 25,27,1989 *** REVIEWS *** TOXICOLOGY REVIEW JPMSAE Journal of Pharmaceutical Sciences. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.50- 1961- Volume(issue)/page/year: 65,315,1976

Safety Information

[ Symbol ]:

GHS07, GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H302 + H312 + H332-H317-H334-H340-H360

[ Precautionary Statements ]:
P201-P261-P280-P308 + P313

[ Personal Protective Equipment ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ Hazard Codes ]:
T:Toxic

[ Risk Phrases ]:
R46;R61;R20/21;R42/43

[ Safety Phrases ]:
S53-S22-S26-S36/37/39-S45

[ RIDADR ]:
UN 2811

[ WGK Germany ]:
3

[ RTECS ]:
TP2300000

[ HS Code ]:
2843900030

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

Cisplatin
1,1-Cyclobutanedicarboxylic acid
Lithium hydroxide

DownStream

azane,cyclobutane-1,1-dicarboxylate,platinum(4+),dihydroxide
Platinum,bis(diethylcarbamodithioato-kS,kS')-, (SP-4-1)- (9CI)

Customs

[ HS Code ]: 2843900030

Articles

Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.

Oncotarget 5(21) , 10434-45, (2014)

The successes of targeted therapeutics against EGFR and ALK in non-small cell lung cancer (NSCLC) have demonstrated the substantial survival gains made possible by precision therapy. However, the majo...

Graphene oxide - gelatin nanohybrids as functional tools for enhanced Carboplatin activity in neuroblastoma cells.

Pharm. Res. 32 , 2132-43, (2015)

Preparation of Nanographene oxide (NGO) - Gelatin hybrids for efficient treatment of Neuroblastoma.Nanohybrids were prepared via non-covalent interactions. Spectroscopic tools have been used to discri...

CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.

Oncotarget 5(15) , 6191-205, (2014)

Malignant mesothelioma is a deadly tumor whose diagnosis and treatment remain very challenging. There is an urgent need to advance our understanding of mesothelioma biology and to identify new molecul...

4-Acetamido-1-benzothiophene-2-carboxylic acid
Tert-butyl 2-amino-3-(3,3-difluorocyclobutyl)propanoate
4-Butyl-3-acetamidobenzoic acid
3-[(3R)-3-acetamidobutyl]benzoic acid
2-methyl-3-[N-(propan-2-yl)acetamido]benzoic acid
benzyl N-[(2R)-1-hydroxypent-4-en-2-yl]carbamate
(2S)-2-(N-methylacetamido)-3-(4-methylphenyl)propanoic acid
3-[4-(Acetamidomethyl)phenyl]-2-methylpropanoic acid
(3S)-3-acetamido-4-(4-methylphenyl)butanoic acid
benzyl N-[(1-hydroxycyclopropyl)methyl]-N-methylcarbamate

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.